ArticleBlood advances2021

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.

Christie P M Verkleij et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.